XML 82 R57.htm IDEA: XBRL DOCUMENT
v3.23.3

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Oct. 01, 2023 | Oct. 02, 2022 | Oct. 01, 2023 | Oct. 02, 2022
Sales by segment of business |  |  |  |
Sales to customers | $ 21,351 | $ 19,996 | $ 63,764 | $ 60,051
Percent Change (as a percent) | 6.80% |  | 6.20% |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 11,996 | 10,794 | $ 34,435 | 31,161
Percent Change (as a percent) | 11.10% |  | 10.50% |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 9,355 | 9,202 | $ 29,329 | 28,890
Percent Change (as a percent) | 1.60% |  | 1.50% |
MEDTECH |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 7,458 | 6,782 | $ 22,727 | 20,651
Percent Change (as a percent) | 10.00% |  | 10.00% |
MEDTECH | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,747 | 3,356 | $ 11,345 | 9,932
Percent Change (as a percent) | 11.60% |  | 14.20% |
MEDTECH | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,711 | 3,426 | $ 11,382 | 10,719
Percent Change (as a percent) | 8.30% |  | 6.20% |
MEDTECH | Interventional Solutions |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,558 | 1,060 | $ 4,681 | 3,202
Percent Change (as a percent) | 47.00% |  | 46.20% |
MEDTECH | Interventional Solutions | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 891 | 547 | $ 2,662 | 1,566
Percent Change (as a percent) | 63.00% |  | 70.00% |
MEDTECH | Interventional Solutions | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 667 | 513 | $ 2,019 | 1,636
Percent Change (as a percent) | 29.90% |  | 23.40% |
MEDTECH | ELECTROPHYSIOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,161 | 973 | $ 3,449 | 2,943
Percent Change (as a percent) | 19.30% |  | 17.20% |
MEDTECH | ELECTROPHYSIOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 611 | 520 | $ 1,791 | 1,489
Percent Change (as a percent) | 17.60% |  | 20.30% |
MEDTECH | ELECTROPHYSIOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 549 | 453 | $ 1,658 | 1,454
Percent Change (as a percent) | 21.20% |  | 14.00% |
MEDTECH | ABIOMED(3) |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 311 | 0 | $ 966 | 0
MEDTECH | ABIOMED(3) | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 254 | 0 | 790 | 0
MEDTECH | ABIOMED(3) | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 57 | 0 | 176 | 0
MEDTECH | OTHER INTERVENTIONAL SOLUTIONS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 87 | 87 | $ 267 | 258
Percent Change (as a percent) | (0.30%) |  | 3.30% |
MEDTECH | OTHER INTERVENTIONAL SOLUTIONS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 26 | 27 | $ 81 | 77
Percent Change (as a percent) | (3.20%) |  | 5.90% |
MEDTECH | OTHER INTERVENTIONAL SOLUTIONS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 61 | 60 | $ 186 | 181
Percent Change (as a percent) | 1.00% |  | 2.20% |
MEDTECH | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,164 | 2,095 | $ 6,674 | 6,440
Percent Change (as a percent) | 3.40% |  | 3.60% |
MEDTECH | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,349 | 1,309 | $ 4,100 | 3,936
Percent Change (as a percent) | 3.10% |  | 4.20% |
MEDTECH | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 815 | 785 | $ 2,574 | 2,504
Percent Change (as a percent) | 3.90% |  | 2.80% |
MEDTECH | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 375 | 352 | $ 1,162 | 1,129
Percent Change (as a percent) | 6.50% |  | 2.90% |
MEDTECH | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 239 | 228 | $ 730 | 693
Percent Change (as a percent) | 4.90% |  | 5.40% |
MEDTECH | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 136 | 124 | $ 432 | 437
Percent Change (as a percent) | 9.30% |  | (1.00%) |
MEDTECH | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 338 | 317 | $ 1,069 | 1,005
Percent Change (as a percent) | 6.70% |  | 6.40% |
MEDTECH | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 207 | 203 | $ 654 | 620
Percent Change (as a percent) | 2.30% |  | 5.60% |
MEDTECH | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 131 | 115 | $ 415 | 386
Percent Change (as a percent) | 14.60% |  | 7.70% |
MEDTECH | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 742 | 717 | $ 2,238 | 2,161
Percent Change (as a percent) | 3.50% |  | 3.50% |
MEDTECH | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 488 | 473 | $ 1,462 | 1,412
Percent Change (as a percent) | 3.20% |  | 3.50% |
MEDTECH | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 253 | 244 | $ 775 | 749
Percent Change (as a percent) | 4.20% |  | 3.50% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 710 | 708 | $ 2,205 | 2,144
Percent Change (as a percent) | 0.20% |  | 2.80% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 415 | 406 | $ 1,254 | 1,211
Percent Change (as a percent) | 2.30% |  | 3.50% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 295 | 303 | $ 952 | 933
Percent Change (as a percent) | (2.60%) |  | 2.00% |
MEDTECH | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,479 | 2,422 | $ 7,507 | 7,306
Percent Change (as a percent) | 2.30% |  | 2.70% |
MEDTECH | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 994 | 984 | $ 2,984 | 2,897
Percent Change (as a percent) | 1.10% |  | 3.00% |
MEDTECH | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,483 | 1,439 | $ 4,522 | 4,410
Percent Change (as a percent) | 3.10% |  | 2.60% |
MEDTECH | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,164 | 1,158 | $ 3,504 | 3,460
Percent Change (as a percent) | 0.50% |  | 1.30% |
MEDTECH | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 455 | 457 | $ 1,365 | 1,328
Percent Change (as a percent) | (0.40%) |  | 2.80% |
MEDTECH | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 709 | 701 | $ 2,139 | 2,132
Percent Change (as a percent) | 1.00% |  | 0.30% |
MEDTECH | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,314 | 1,264 | $ 4,002 | 3,846
Percent Change (as a percent) | 4.00% |  | 4.10% |
MEDTECH | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 540 | 527 | $ 1,619 | 1,569
Percent Change (as a percent) | 2.40% |  | 3.20% |
MEDTECH | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 775 | 737 | $ 2,383 | 2,277
Percent Change (as a percent) | 5.10% |  | 4.70% |
MEDTECH | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,256 | 1,206 | $ 3,864 | 3,704
Percent Change (as a percent) | 4.20% |  | 4.30% |
MEDTECH | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 512 | 517 | $ 1,599 | 1,534
Percent Change (as a percent) | (1.00%) |  | 4.20% |
MEDTECH | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 744 | 689 | $ 2,265 | 2,170
Percent Change (as a percent) | 8.10% |  | 4.40% |
MEDTECH | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 928 | 908 | $ 2,820 | 2,712
Percent Change (as a percent) | 2.20% |  | 4.00% |
MEDTECH | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 399 | 405 | $ 1,252 | 1,179
Percent Change (as a percent) | (1.20%) |  | 6.20% |
MEDTECH | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 529 | 503 | $ 1,568 | 1,533
Percent Change (as a percent) | 4.90% |  | 2.30% |
MEDTECH | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 328 | 298 | $ 1,044 | 992
Percent Change (as a percent) | 10.30% |  | 5.30% |
MEDTECH | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 112 | 112 | $ 346 | 355
Percent Change (as a percent) | (0.10%) |  | (2.50%) |
MEDTECH | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 216 | 186 | $ 698 | 637
Percent Change (as a percent) | 16.60% |  | 9.60% |
Innovative Medicine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 13,893 | 13,214 | $ 41,037 | 39,400
Percent Change (as a percent) | 5.10% |  | 4.20% |
Innovative Medicine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 8,249 | 7,438 | $ 23,090 | 21,229
Percent Change (as a percent) | 10.90% |  | 8.80% |
Innovative Medicine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5,644 | 5,776 | $ 17,947 | 18,171
Percent Change (as a percent) | (2.30%) |  | (1.20%) |
Innovative Medicine | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,849 | 4,287 | $ 13,457 | 12,817
Percent Change (as a percent) | 13.10% |  | 5.00% |
Innovative Medicine | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,193 | 2,876 | $ 8,506 | 8,230
Percent Change (as a percent) | 11.00% |  | 3.30% |
Innovative Medicine | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,656 | 1,411 | $ 4,951 | 4,587
Percent Change (as a percent) | 17.40% |  | 7.90% |
Innovative Medicine | Immunology | REMICADE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 461 | 558 | $ 1,410 | 1,868
Percent Change (as a percent) | (17.40%) |  | (24.50%) |
Innovative Medicine | Immunology | REMICADE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 296 | 350 | $ 849 | 1,099
Percent Change (as a percent) | (15.40%) |  | (22.70%) |
Innovative Medicine | Immunology | REMICADE | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 38 | 39 | $ 112 | 163
Percent Change (as a percent) | (2.50%) |  | (31.30%) |
Innovative Medicine | Immunology | REMICADE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 127 | 169 | $ 449 | 606
Percent Change (as a percent) | (25.10%) |  | (25.90%) |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 629 | 545 | $ 1,695 | 1,682
Percent Change (as a percent) | 15.30% |  | 0.80% |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 310 | 298 | $ 866 | 886
Percent Change (as a percent) | 3.90% |  | (2.30%) |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 319 | 248 | $ 829 | 797
Percent Change (as a percent) | 29.10% |  | 4.10% |
Innovative Medicine | Immunology | STELARA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,864 | 2,449 | $ 8,105 | 7,336
Percent Change (as a percent) | 16.90% |  | 10.50% |
Innovative Medicine | Immunology | STELARA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,912 | 1,655 | $ 5,180 | 4,766
Percent Change (as a percent) | 15.50% |  | 8.70% |
Innovative Medicine | Immunology | STELARA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 951 | 794 | $ 2,925 | 2,571
Percent Change (as a percent) | 19.90% |  | 13.80% |
Innovative Medicine | Immunology | TREMFYA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 891 | 729 | $ 2,237 | 1,916
Percent Change (as a percent) | 22.20% |  | 16.80% |
Innovative Medicine | Immunology | TREMFYA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 634 | 530 | $ 1,490 | 1,303
Percent Change (as a percent) | 19.60% |  | 14.40% |
Innovative Medicine | Immunology | TREMFYA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 258 | 200 | $ 747 | 613
Percent Change (as a percent) | 29.00% |  | 21.90% |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2 | 5 | $ 9 | 14
Percent Change (as a percent) | (47.10%) |  | (36.10%) |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2 | 5 | $ 9 | 14
Percent Change (as a percent) | (47.10%) |  | (36.10%) |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
Innovative Medicine | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 859 | 1,295 | $ 3,566 | 3,908
Percent Change (as a percent) | (33.60%) |  | (8.70%) |
Innovative Medicine | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 360 | 390 | $ 1,147 | 1,266
Percent Change (as a percent) | (7.80%) |  | (9.40%) |
Innovative Medicine | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 500 | 905 | $ 2,420 | 2,642
Percent Change (as a percent) | (44.80%) |  | (8.40%) |
Innovative Medicine | Infectious Diseases | COVID-19 |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 41 | 489 | $ 1,073 | 1,490
Percent Change (as a percent) | (91.50%) |  | (27.90%) |
Innovative Medicine | Infectious Diseases | COVID-19 | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 120
Innovative Medicine | Infectious Diseases | COVID-19 | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 41 | 489 | $ 1,073 | 1,370
Percent Change (as a percent) | (91.50%) |  | (21.60%) |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 297 | 245 | $ 843 | 718
Percent Change (as a percent) | 21.00% |  | 17.50% |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 9 | 9 | $ 26 | 27
Percent Change (as a percent) | 10.20% |  | (0.50%) |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 287 | 237 | $ 816 | 691
Percent Change (as a percent) | 21.40% |  | 18.20% |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 447 | 485 | $ 1,415 | 1,450
Percent Change (as a percent) | (7.80%) |  | (2.40%) |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 345 | 372 | $ 1,105 | 1,096
Percent Change (as a percent) | (7.30%) |  | 0.90% |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 102 | 112 | $ 310 | 354
Percent Change (as a percent) | (9.50%) |  | (12.50%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES( |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 74 | 77 | $ 235 | 251
Percent Change (as a percent) | (3.60%) |  | (6.40%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5 | 10 | $ 15 | 24
Percent Change (as a percent) | (42.70%) |  | (35.50%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 69 | 68 | $ 220 | 228
Percent Change (as a percent) | 2.00% |  | (3.40%) |
Innovative Medicine | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,742 | 1,681 | $ 5,339 | 5,156
Percent Change (as a percent) | 3.60% |  | 3.50% |
Innovative Medicine | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,036 | 919 | $ 3,043 | 2,658
Percent Change (as a percent) | 12.70% |  | 14.50% |
Innovative Medicine | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 706 | 763 | $ 2,296 | 2,498
Percent Change (as a percent) | (7.40%) |  | (8.10%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 189 | 158 | $ 603 | 476
Percent Change (as a percent) | 20.00% |  | 26.70% |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 57 | 41 | $ 191 | 114
Percent Change (as a percent) | 38.10% |  | 67.40% |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 133 | 117 | $ 412 | 362
Percent Change (as a percent) | 13.60% |  | 13.80% |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,029 | 1,031 | $ 3,104 | 3,132
Percent Change (as a percent) | (0.20%) |  | (0.90%) |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 730 | 684 | $ 2,164 | 2,036
Percent Change (as a percent) | 6.80% |  | 6.30% |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 299 | 348 | $ 940 | 1,097
Percent Change (as a percent) | (14.00%) |  | (14.30%) |
Innovative Medicine | Neuroscience | SPRAVATO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 183 | 100 | $ 483 | 255
Percent Change (as a percent) | 82.10% |  | 88.80% |
Innovative Medicine | Neuroscience | SPRAVATO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 154 | 88 | $ 409 | 223
Percent Change (as a percent) | 75.10% |  | 83.10% |
Innovative Medicine | Neuroscience | SPRAVATO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 29 | 12 | $ 74 | 32
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 340 | 393 | $ 1,149 | 1,293
Percent Change (as a percent) | (13.20%) |  | (11.00%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 94 | 106 | $ 278 | 285
Percent Change (as a percent) | (11.30%) |  | (2.30%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 245 | 286 | $ 870 | 1,007
Percent Change (as a percent) | (13.90%) |  | (13.50%) |
Innovative Medicine | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,533 | 4,064 | $ 13,043 | 12,056
Percent Change (as a percent) | 11.50% |  | 8.20% |
Innovative Medicine | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,219 | 1,812 | $ 6,177 | 5,073
Percent Change (as a percent) | 22.50% |  | 21.80% |
Innovative Medicine | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,313 | 2,252 | $ 6,865 | 6,983
Percent Change (as a percent) | 2.70% |  | (1.70%) |
Innovative Medicine | Oncology | CARVYKTI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 152 | 55 | $ 341 | 79
Innovative Medicine | Oncology | CARVYKTI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 140 | 55 | 324 | 79
Innovative Medicine | Oncology | CARVYKTI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 12 | 0 | 17 | 0
Innovative Medicine | Oncology | DARZALEX |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,499 | 2,052 | $ 7,194 | 5,894
Percent Change (as a percent) | 21.80% |  | 22.10% |
Innovative Medicine | Oncology | DARZALEX | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,369 | 1,097 | $ 3,882 | 3,071
Percent Change (as a percent) | 24.80% |  | 26.40% |
Innovative Medicine | Oncology | DARZALEX | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,130 | 955 | $ 3,312 | 2,823
Percent Change (as a percent) | 18.30% |  | 17.30% |
Innovative Medicine | Oncology | ERLEADA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 631 | 490 | $ 1,740 | 1,340
Percent Change (as a percent) | 28.70% |  | 29.80% |
Innovative Medicine | Oncology | ERLEADA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 288 | 254 | $ 778 | 693
Percent Change (as a percent) | 12.90% |  | 12.20% |
Innovative Medicine | Oncology | ERLEADA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 342 | 235 | $ 961 | 647
Percent Change (as a percent) | 45.80% |  | 48.70% |
Innovative Medicine | Oncology | IMBRUVICA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 808 | 911 | $ 2,476 | 2,918
Percent Change (as a percent) | (11.30%) |  | (15.20%) |
Innovative Medicine | Oncology | IMBRUVICA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 264 | 353 | $ 796 | 1,072
Percent Change (as a percent) | (25.20%) |  | (25.80%) |
Innovative Medicine | Oncology | IMBRUVICA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 545 | 559 | $ 1,681 | 1,847
Percent Change (as a percent) | (2.50%) |  | (9.00%) |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 214 | 456 | $ 686 | 1,500
Percent Change (as a percent) | (53.00%) |  | (54.20%) |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 16 | 16 | $ 41 | 54
Percent Change (as a percent) | (2.80%) |  | (24.90%) |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 199 | 440 | $ 646 | 1,446
Percent Change (as a percent) | (54.90%) |  | (55.30%) |
Innovative Medicine | Oncology | OTHER ONCOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 229 | 100 | $ 605 | 324
Percent Change (as a percent) |  |  | 86.50% |
Innovative Medicine | Oncology | OTHER ONCOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 143 | 37 | $ 357 | 104
Innovative Medicine | Oncology | OTHER ONCOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 86 | 64 | $ 248 | 220
Percent Change (as a percent) | 34.50% |  | 12.50% |
Innovative Medicine | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 954 | 852 | $ 2,798 | 2,547
Percent Change (as a percent) | 12.00% |  | 9.90% |
Innovative Medicine | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 680 | 604 | $ 1,964 | 1,736
Percent Change (as a percent) | 12.60% |  | 13.10% |
Innovative Medicine | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 274 | 247 | $ 835 | 810
Percent Change (as a percent) | 10.50% |  | 3.00% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 490 | 441 | $ 1,437 | 1,322
Percent Change (as a percent) | 11.20% |  | 8.70% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 323 | 289 | $ 924 | 827
Percent Change (as a percent) | 12.20% |  | 11.80% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 166 | 152 | $ 512 | 495
Percent Change (as a percent) | 9.30% |  | 3.50% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 402 | 333 | $ 1,163 | 986
Percent Change (as a percent) | 20.70% |  | 18.00% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 336 | 283 | $ 978 | 824
Percent Change (as a percent) | 18.90% |  | 18.70% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 66 | 50 | $ 185 | 162
Percent Change (as a percent) | 30.90% |  | 14.10% |
Innovative Medicine | Pulmonary Hypertension | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 63 | 78 | $ 199 | 239
Percent Change (as a percent) | (19.80%) |  | (16.90%) |
Innovative Medicine | Pulmonary Hypertension | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 20 | 33 | $ 61 | 86
Percent Change (as a percent) | (37.10%) |  | (28.40%) |
Innovative Medicine | Pulmonary Hypertension | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 42 | 46 | $ 137 | 154
Percent Change (as a percent) | (7.50%) |  | (10.50%) |
Innovative Medicine | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 957 | 1,034 | $ 2,834 | 2,916
Percent Change (as a percent) | (7.50%) |  | (2.80%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 763 | 837 | $ 2,254 | 2,266
Percent Change (as a percent) | (8.80%) |  | (0.50%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 194 | 198 | $ 580 | 651
Percent Change (as a percent) | (2.10%) |  | (10.80%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 332 | 345 | $ 994 | 1,110
Percent Change (as a percent) | (3.80%) |  | (10.50%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 139 | 147 | $ 414 | 459
Percent Change (as a percent) | (6.10%) |  | (9.90%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 194 | 198 | $ 580 | 651
Percent Change (as a percent) | (2.10%) |  | (10.80%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 625 | 689 | $ 1,840 | 1,806
Percent Change (as a percent) | (9.40%) |  | 1.90% |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 625 | 689 | $ 1,840 | 1,806
Percent Change (as a percent) | (9.40%) |  | 1.90% |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | $ 0 | $ 0 | $ 0
Percent Change (as a percent) | 0.00% |  | 0.00% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ElectrophysiologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_AbiomedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OtherInterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPRAVATOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CARVYKTIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |